Our Programs
Targeting Rare and Infectious Diseases
AVI BioPharma’s therapeutic development programs include lead candidates for Duchenne muscular dystrophy, hemorrhagic virus infections and influenza.
This page was last updated on June 27, 2011.
Research and Development Pipeline
| Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | |
| DMD - Exon 51 AVI-4658 |
|
||||
| DMD - Exon 50 AVI-5038 |
|
||||
| Ebola VIrus AVI-6002 |
|
||||
| Marburg Virus AVI-6003 |
|
||||
| Junin Virus AVI-7012 |
|
||||
| Influenza Therapy AVI-7100 |
|
||||
| Dengue Virus AVI-6006 |
|
||||
